Scholarly Index
Paul J. Rowe
Sanofi (United States); 1,591 total citations; 137 total publications; best world rank #51
Sanofi (United States)
1,591Total citations
137Total publications
21H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| IL-33, ST2, and ILC Pathways | 2021-2025 | 51 | US 21 | 96.00 |
| Asthma and respiratory diseases | 2021-2025 | 186 | US 51 | 98.22 |
| Eosinophilic Esophagitis | 2021-2025 | 209 | US 84 | 95.18 |
| Sinusitis and nasal conditions | 2021-2025 | 161 | US 63 | 93.52 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 466 | US 118 | 92.65 |
| Respiratory and Cough-Related Research | 2021-2025 | 265 | US 55 | 91.24 |
| Pediatric health and respiratory diseases | 2021-2025 | 872 | US 141 | 72.28 |